Summary
On January 12, 2026, Vincenza Trivigno assumes the position of Director of Swissmedic. The 55-year-old economist succeeds Raimund Bruhin, who has headed the Swiss medicines authority since 2018. Trivigno brings extensive management experience from both the public and private sectors, most recently as CEO of VAMED Switzerland Group. She takes over leadership during a phase of important strategic challenges, including digitalization and international cooperation.
People
- Vincenza Trivigno – new Director of Swissmedic
- Raimund Bruhin – previous Director (retirement February 2026)
Topics
- Leadership change in Swiss authorities
- Digitalization and modernization
- International cooperation in healthcare
- Strategic realignment 2027-2030
Detailed Summary
Vincenza Trivigno takes office as Director of the Swiss Medicines Institute, assuming a key position in Swiss health policy. The economist has a broad professional background: she served as State Secretary of the Canton of Aargau, Secretary General of the Health Department of Zug, member of the executive board of Stadler Rail, and worked at Interpharma. From 2021 to 2025, she led VAMED Switzerland Group (now VITREA Switzerland) as CEO, managing several rehabilitation clinics. Her academic training was completed at renowned institutions including the University of St. Gallen, the London School of Economics, and Harvard Law School.
Trivigno was also Vice President of the Swissmedic Institute Board from 2016 to 2021, and thus knows the organization from an insider perspective. The Federal Council appointed her as the new Director on the recommendation of the Institute Board on June 25, 2025.
The new Director takes over Swissmedic during a period of significant change. Central tasks include consolidating the financial framework, advancing digitalization, and strengthening international cooperation. Together with the Institute Board and management, she will develop the Strategic Objectives 2027-2030 and submit them to the Federal Council for approval.
Swissmedic is part of Switzerland's economic and security supervisory authorities and belongs to the decentralized federal administration. The authority is scientifically independent, politically neutral, and maintains its own budget. Its core tasks include the approval of medicines, market surveillance, authorization of clinical trials, and the issuance of operating permits for manufacturing and wholesale trading companies.
Key Messages
- Leadership Change: Vincenza Trivigno takes over the leadership of Swissmedic on January 12, 2026
- Experience: Long-standing management experience in healthcare, public administration, and the private sector
- Insider Knowledge: Previous role as Vice President of the Institute Board enables smooth transition
- Strategic Priorities: Digitalization, financial stability, and international cooperation are in focus
- New Strategic Objectives: Development of strategic objectives 2027-2030 as a central task
- Language Skills: German, Italian, French, and English
Stakeholders & Affected Parties
| Stakeholder | Impact |
|---|---|
| Pharmaceutical and Medical Device Industry | Continuity in approval procedures; potentially new impetus through digitalization |
| Patients and Population | Improved safety through modernized processes; faster approvals through digitalization |
| Swissmedic Employees | Leadership change with a known personality; clear strategic direction |
| Federal Council and Federal Administration | Stronger international cooperation and modernization |
| Raimund Bruhin | Well-deserved retirement after 8 years in office |
Opportunities & Risks
| Opportunities | Risks |
|---|---|
| Experience from private sector brings innovation | Transition from private sector to authority requires adjustment |
| Digitalization can accelerate approval procedures | Financial consolidation could limit resources |
| Insider knowledge shortens onboarding time | High expectations for rapid strategy implementation |
| International networks strengthen Switzerland's position | External pressure from global pharmaceutical developments |
| Multilingual competence promotes international cooperation | Cultural differences between authority and private sector |
Action Relevance
Relevant for decision-makers:
- Monitoring Strategy Implementation: The new Strategic Objectives 2027-2030 should be available promptly and be ambitious
- Digitalization Projects: Concrete projects for modernizing approval procedures should be prioritized
- International Cooperation: Strengthening collaboration with European and global regulators
- Financial Planning: Resource allocation to support digitalization objectives
- Employee Communication: Clear communication of leadership vision to the organization
Quality Assurance & Fact-Checking
- [x] Central statements and figures verified
- [x] Unconfirmed data marked with ⚠️
- [x] Official press release verified as primary source
- [x] No apparent bias or political one-sidedness
Supplementary Research
- Swissmedic Annual Report 2025 – Financial situation and performance indicators
- Federal Office of Public Health (FOPH) – Strategic direction of the Swiss healthcare system
- European Medicines Agency (EMA) – International standards for drug approval
Bibliography
Primary Source:
Press Release of the Federal Office of Public Health – "Leadership Change at Swissmedic: Director Vincenza Trivigno Takes Office" (January 12, 2026)
https://www.news.admin.ch/de/newnsb/WDe0XvTzeBE6YUcYNumEl
Supplementary Sources:
- Swissmedic – Official website and organizational information
- Federal Council – Appointment decision from June 25, 2025
- Interpharma – Industry information on the Swiss pharmaceutical market
Verification Status: ✓ Facts checked on January 12, 2026
Footer (Transparency Notice)
This text was created with the support of Claude.
Editorial responsibility: clarus.news | Fact-checking: January 12, 2026